Table 1.
Patient and tumor characteristics of the patients included in the translational TEX trial
| Patients |
||
|---|---|---|
| Number | Percent | |
| Age at primary tumor diagnosis, years | ||
| <45 | 27 | 24.3 |
| 45–55 | 45 | 40.5 |
| >55 | 39 | 35.2 |
| Calendar period of primary tumor diagnosis | ||
| 1985–1989 | 4 | 3.6 |
| 1990–1994 | 6 | 5.4 |
| 1995–1999 | 26 | 23.4 |
| 2000–2007 | 75 | 67.6 |
| Primary tumor characteristics | ||
| Estrogen receptor status | ||
| Positive | 65 | 62.5 |
| Negative | 39 | 37.5 |
| Unknown | 7 | – |
| Progesterone receptor status | ||
| Positive | 47 | 48.5 |
| Negative | 50 | 51.5 |
| Unknown | 14 | – |
| Elston–Ellis tumor grade | ||
| 1 | 4 | 4.9 |
| 2 | 35 | 42.7 |
| 3 | 43 | 52.4 |
| Unknown | 29 | – |
| T stage at diagnosis | ||
| T1 | 36 | 33.3 |
| T2 | 43 | 39.8 |
| T3 | 13 | 12.1 |
| T4 | 16 | 14.8 |
| Unknown | 3 | – |
| N stage at diagnosis | ||
| N0 | 32 | 30.2 |
| N1 | 65 | 61.3 |
| N2 | 8 | 7.5 |
| N3 | 1 | 1.0 |
| Unknown | 5 | – |
| M stage at diagnosis | ||
| M0 | 85 | 76.6 |
| M1 | 26 | 23.4 |
| Adjuvant therapy | ||
| Endocrine therapy | ||
| Yes | 47 | 42.3 |
| No | 64 | 57.7 |
| Radiotherapy | ||
| Yes | 64 | 57.7 |
| No | 47 | 42.3 |
| Chemotherapy | ||
| Yes | 48 | 43.2 |
| No | 63 | 56.8 |